[The Experience of Use Triple Antithrombotic Therapy in Patients With Acute Coronary Syndrome and Atrial Fibrillation].
In real life to evaluate the effectiveness and safety of apixaban with double antiplatelet therapy for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and the recent episode of acute coronary syndrome without ST segment elevation. 8 patients with atrial fibrillation and the recent (8-14 days after the onset of symptoms of ACS) episode of acute coronary syndrome without ST segment elevation were involved into the research. The effectiveness (deaths, stroke and systemic embolism) and the safety (major clinically significant and not significant bleeding) were investigated within 3 months. There were no any strokes, systemic embolism, deaths during observational period. Nasal and mild gingival hemorrhages (not requiring medical intervention) were noted in 2 patients during the first month of treatment and two patients experienced non-permanent petechiae. Major and clinically significant bleeding was not registered. onclusions: the use of oral anticoagulant apixaban 5 mg BID or 2.5 mg BID with double antiplatelet therapy in patients with non-valvular atrial fibrillation and the recent episode of acute coronary syndrome without ST segment elevation is effective and safe for the prevention of stroke and systemic embolism during 3 months of treatment. Future researches are required.